Monday, June 13, 2016
A significant number of children experience long-term health conditions. This group’s health needs have not previously been given the research priority that they deserve. The NIHR has invested £21 million ($23.4 million) in 35 new studies focusing on improving the health outcomes for children and young people.
Hemispherx Biopharma has executed an amended and restated agreement with Impatients, a Netherlands-based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.
ClinTec International is expanding, opening two new offices in Spain, and appointing Carlos Palacios as the company’s new regional manager for Spain and Portugal.
Pfizer has announced results of two phase III studies demonstrating the immunogenicity of TRUMENBA (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responses against ten additional MnB strains, in both adolescents and young adults.
Veristat, a full service CRO, is expanding its clinical research offerings into Europe through the acquisition of U.K.-based CRO Spero Oncology. Spero Oncology specializes in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the acquisition of Spero Oncology, Veristat now offers its clients full clinical operations support in Europe including feasibility studies, legal representation in the European Union, clinical monitoring, project management, protocol writing and regulatory strategy.
India has 16% of the world’s population and accounts for 20% of the world’s disease burden, yet less than 1.4% of global clinical trials are conducted there. A series of blemishes in clinical research has shaken worldwide confidence—but experts say positive steps have been taken to bring hope for the future.
The pharmaceutical industry in Italy is set to decline from $21.3 billion in 2016 to $18.6 billion by 2020, at a negative compound annual growth rate of 3.3%, primarily due to the country’s struggling economy, according to research and consulting firm GlobalData.
Giving a major boost to open science in Europe, the Commission has presented its blueprint for cloud-based services and world-class data infrastructure to ensure science, business and public services reap benefits of big data revolution.
GE Healthcare’s life sciences business has officially launched a new research scheme to help foster Turkish bioprocessing development and manufacturing, through its latest Fast Trak Bioprocessing Technology and Training Laboratory in Istanbul. Based in GE’s Turkey Innovation Center, the R&D Laboratory is well-located to support the region’s rapidly growing biopharmaceutical and biotech industry, and help position Turkey as a global R&D and manufacturing hub.